“The discovery of ARGX-116 is truly one of collaboration, utilizing Staten’s unique expertise in dyslipidemia and our novel SIMPLE AntibodyTM platform to develop an antagonizing antibody against ApoC3, a target involved in triglyceride metabolism,” commented Tim Van Hauwermeiren, Chief Executive Officer of argenx. “We are highly encouraged by Staten’s decision to pursue further development of this exciting molecule and recognize that strategic collaborations like this one are a fundamental pillar of our mission allowing us to be a leader in developing therapeutic antibodies.”
argenx began its collaboration with Staten Biotech in 2015 as part of a research collaboration through its Innovative Access Program. Under the terms of the agreement, Staten will be responsible for additional development of ARGX-116, and argenx is eligible to receive a double-digit portion on income related to the product. Additional financial details of the collaboration have not been disclosed.
More news on Argenx
